Labs are seeing fewer applications from international students and researchers, and some doctoral students are considering ...

"Blue zones" as a concept have strayed far and wide from their humble roots, write Shelley Wood and Eric Topol.

China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.

Megan Molteni reports on discoveries from the frontiers of genomic medicine, neuroscience, and reproductive tech. She joined STAT in 2021 after covering health and science at WIRED. You can reach ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

The likelihood of snagging NIH grants has plunged to historic lows, forcing academic researchers to resort to a variety of ...

A federal appeals court has restricted access to one of the most common means of abortion in the U.S. by blocking the mailing ...

Katherine Szarama, who joined the FDA last year to serve as Vinay Prasad’s deputy, will now fill his shoes at CBER.

For the first time, FDA regulators will be able to see what’s happening in a clinical trial, looking at endpoints in the ...

Examining the past statements and writings of Trump's third surgeon general nominee, Dr. Nicole Saphier, on vaccines, autism, ...

The thinking about what risk Covid poses — or doesn't pose — has shifted in recent years. What does it mean for you?

J. Craig Venter, the scientist whose relentless ambition helped turn genetics from an artisanal trade into an industrialized ...